Life Science Instruments: Company Announcements

DeltaDOT appointed Richard Lingard as vice president of Sales. He was previously director of Strategic Alliances for Invitrogen.

SRU Biosystems exclusively licensed Novartis’s Evanescent Resonance technology for drug discovery applications. The technology enables enhanced sensitivity to fluorescence-based assays.

In April, Caliper Life Sciences named John DelliSanti executive vice president and chief commercial officer. He previously led Americas Commercial Operations for Invitrogen.

Caliper Life Sciences exclusively licensed most of Monogram Biosciences’ microfluidics patent portfolio. The related intellectual property originates with ACLARA Biosciences. Monogram retains the right to practice the technology for use with its eTag technology.

BioTrove appointed Gregory C. Critchfield, MD, MS, to its Board in April. He is president of Myriad Genetic Laboratories.

In April, Transgenomic purchased certain assets of SpectruMedix, a maker of capillary electrophoresis instruments, that discontinued operations in March.

Transgenomic, which had been SpectruMedix’s exclusive European distributor, will continue to support SpectruMedix products.

NextGen expects that over 50% of its 2007 revenues will come from its contract services business rather than products. In 2006, sales increased over 40% with instruments constituting 60% of sales. The company has appointed Mike Pisano, president of Proteomic Research Services (see IBO 1/31/07), as chief scientific officer and plans to expand its US-based fee-for-service business.

US Genomics named Salvatore J. Salamone, PhD, to its Board. He is chairman and CEO of Saladax Biomedical.

ART Advanced Research Technologies extended its distribution agreement with GE Healthcare (see IBO 10/15/03).

Isogen Life Science BV will distribute Attana AB’s biosensor systems in Benelux, Spain and Portugal.

< | >